WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H575089
CAS#: 84210-80-0 (CHA salt)
Description: Mafosfamide cyclohexylamine salt is a metabolite of cyclophosphamide.
Hodoodo Cat#: H575089
Name: Mafosfamide cyclohexylamine salt
CAS#: 84210-80-0 (CHA salt)
Chemical Formula: C15H32Cl2N3O5PS2
Exact Mass: 499.09
Molecular Weight: 500.430
Elemental Analysis: C, 36.00; H, 6.45; Cl, 14.17; N, 8.40; O, 15.99; P, 6.19; S, 12.81
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 88859-04-5 (free acid) 84211-05-2 (sodium) 84210-80-0 (CHA salt) 98845-64-8 (lysine)
Synonym: Asta Z 7557; ASTA 7557; ASTA7557; ASTA-7557; CCRIS 2542; Mafosfamide cyclohexylamine salt
IUPAC/Chemical Name: cyclohexanamine 2-(((2S,4R)-2-(bis(2-chloroethyl)amino)-2-oxido-1,3,2-oxazaphosphinan-4-yl)thio)ethane-1-sulfonate
InChi Key: AJOJXYODECALSX-BCPQDLGFSA-N
InChi Code: InChI=1S/C9H19Cl2N2O5PS2.C6H13N/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17;7-6-4-2-1-3-5-6/h9H,1-8H2,(H,12,14)(H,15,16,17);6H,1-5,7H2/t9-,19+;/m1./s1
SMILES Code: NC1CCCCC1.OS(=O)(=O)CCS[C@@H]2CCO[P@@](=O)(N2)N(CCCl)CCCl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 500.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1. Mazur L, Opydo-Chanek M, Stojak M, Wojcieszek K. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials. Anticancer Res. 2012 Jul;32(7):2783-9. PMID: 22753738.
2. Jacob E, Scorsone K, Blaney SM, D'Argenio DZ, Berg SL. Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatr Blood Cancer. 2008 Apr;50(4):757-60. doi: 10.1002/pbc.21330. PMID: 17849472; PMCID: PMC2975705.
